Shirish M. Gadgeel

Shirish M. Gadgeel's AcademicInfluence.com Rankings

Shirish M. Gadgeel

Philosophy

#8082

World Rank

#11399

Historical Rank

Logic

#5114

World Rank

#6480

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Shirish M. Gadgeel's Degrees

Masters Medicine University of Mumbai
Doctorate Internal Medicine University of Mumbai

Why Is Shirish M. Gadgeel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Shirish M. Gadgeel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer (2018) (3740)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2017) (3388)
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer (2017) (1553)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. (2016) (1148)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. (2014) (617)
Rociletinib in EGFR-mutated non-small-cell lung cancer. (2015) (547)
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. (2016) (491)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2020) (470)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer (2016) (453)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. (2018) (451)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. (2016) (421)
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. (2005) (383)
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. (2015) (367)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. (2007) (283)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. (2019) (281)
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma (2016) (242)
TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. (2020) (228)
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer (2010) (223)
Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. (2011) (215)
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. (2019) (209)
Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. (1998) (201)
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study (2018) (194)
The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology Interactions. (2016) (179)
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium (2021) (178)
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer (2018) (175)
24‐Month Overall Survival from KEYNOTE‐021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First‐Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer (2019) (166)
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma (2017) (158)
First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). (2014) (154)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. (2016) (153)
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686) (2016) (153)
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive‐Stage Small Cell Lung Cancer (SCLC) (2018) (149)
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer (2018) (147)
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. (2013) (144)
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib (2014) (133)
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs (2013) (132)
Up-Regulation of Sonic Hedgehog Contributes to TGF-β1-Induced Epithelial to Mesenchymal Transition in NSCLC Cells (2011) (127)
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. (2021) (118)
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib (2019) (113)
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. (2015) (112)
Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189. (2021) (109)
Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. (1995) (106)
Pembrolizumab in Combination With Erlotinib or Gefitinib as First‐Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation (2019) (104)
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. (2008) (100)
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. (2021) (100)
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. (2019) (97)
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. (2013) (94)
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC (2016) (88)
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509 (2011) (87)
Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). (2019) (87)
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. (2019) (84)
Racial differences in lung cancer (2003) (83)
Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. (2016) (82)
Impact of race in lung cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database. (2001) (81)
Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data (2016) (80)
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival (2015) (80)
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (2020) (77)
Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design (2005) (77)
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. (2022) (77)
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407 (2019) (75)
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. (2019) (74)
ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC (2018) (74)
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. (2015) (73)
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. (2008) (72)
Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program. (1999) (72)
Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer (2011) (71)
OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC (2019) (70)
Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data (2018) (70)
Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. (2014) (67)
Treatment of lung cancer. (2012) (66)
Phase II Study of Paclitaxel and Carboplatin in Patients With Advanced Gastric Cancer (2003) (66)
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer (2017) (65)
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors (2008) (65)
Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC. (2019) (64)
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC) (2007) (62)
Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H. (2016) (62)
Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines (2009) (62)
Percutaneous cryoablation of metastatic lesions from non-small-cell lung carcinoma: initial survival, local control, and cost observations. (2012) (60)
KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. (2019) (60)
Modern staging of small cell lung cancer. (2013) (59)
Predictors of enrollment in lung cancer clinical trials (2006) (59)
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. (2018) (58)
Chronic Obstructive Lung Diseases and Risk of Non-small Cell Lung Cancer in Women (2009) (56)
Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). (2020) (55)
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. (2019) (55)
Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). (2018) (55)
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. (2007) (54)
Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists. (2017) (53)
Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2020) (52)
An Educational Video to Increase Clinical Trials Enrollment among Lung Cancer Patients (2008) (51)
XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib (2012) (51)
Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials. (2020) (50)
OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC (2019) (49)
Soy Isoflavones Augment Radiation Effect by Inhibiting APE1/Ref-1 DNA Repair Activity in Non-small Cell Lung Cancer (2011) (49)
Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling (2019) (48)
MET/HGF pathway activation as a paradigm of resistance to targeted therapies. (2017) (48)
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial (2018) (48)
Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives (2012) (46)
KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC (2019) (46)
PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). (2010) (45)
An educational video to increase clinical trials enrollment among breast cancer patients (2009) (44)
Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC). (2018) (44)
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials (2020) (44)
Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer (2016) (43)
Paclitaxel, cisplatin, and 5‐fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck (1999) (42)
Lung Cancer and Personalized Medicine (2016) (42)
Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer (2011) (42)
Molecular therapeutic targets in non-small cell lung cancer (2020) (41)
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors (2016) (41)
Analysis and Reproducibility of 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer (2008) (41)
Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer (2012) (39)
First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. (2013) (39)
Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). (2017) (39)
Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer (2015) (39)
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. (2010) (39)
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. (2017) (38)
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. (2015) (38)
Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. (2016) (37)
Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury. (2011) (37)
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. (2019) (36)
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. (2017) (35)
Patterns of care in a population‐based sample of soft tissue sarcoma patients in the United States (2009) (34)
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. (2017) (34)
OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01 (2021) (33)
MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC (2017) (33)
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. (2017) (33)
Symptom and Quality of Life Improvement in LUX‐Lung 8, an Open‐Label Phase III Study of Second‐Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First‐Line Platinum‐Based Chemotherapy (2018) (33)
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer (2018) (33)
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors (2018) (33)
Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer (2015) (33)
The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. (2010) (32)
Retracted: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor (2007) (32)
Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2 (2008) (32)
Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer (2009) (31)
Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions (2019) (30)
Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort (2019) (30)
Risk of Lung Cancer Associated with COPD Phenotype Based on Quantitative Image Analysis (2016) (30)
A phase I study of flavopiridol and docetaxel (2006) (29)
Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). (2009) (28)
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI‐906) or Placebo in Chemotherapy‐Naive Patients With Non–Small‐Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations (2017) (28)
Radioprotection of Lung Tissue by Soy Isoflavones (2013) (28)
Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic (2020) (28)
Immune Checkpoint Inhibitors in the Management of Lung Cancer. (2018) (28)
Association of PD-L2 expression in human tumors with atezolizumab activity. (2016) (27)
Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts). (2017) (27)
Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non–Small-Cell Lung Cancer Cells to Pemetrexed (2014) (27)
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189 (2021) (27)
Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study. (2017) (27)
Fibroblast Growth Factor Receptor 1 Amplification in Non-Small Cell Lung Cancer by Quantitative Real-Time PCR (2013) (26)
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. (2018) (26)
Personalized Therapy of Non-small Cell Lung Cancer (NSCLC). (2016) (26)
Phase II Study of Celecoxib and Docetaxel in Non-small Cell Lung Cancer (NSCLC) Patients with Progression after Platinum-Based Therapy (2008) (26)
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. (2010) (25)
Differential effect of soy isoflavones in enhancing high intensity radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinoma. (2013) (25)
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528 (2013) (25)
PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses (2017) (25)
Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer (2011) (25)
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). (2019) (24)
Phase I Study of Bryostatin 1 and Gemcitabine (2006) (24)
OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab (2017) (24)
Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study (2014) (24)
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. (2017) (23)
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. (2013) (23)
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution (2019) (22)
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. (2015) (22)
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC (2017) (22)
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC). (2006) (21)
A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. (1997) (21)
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). (2015) (21)
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma (2016) (21)
A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor (2006) (20)
First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. (2017) (20)
Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC (2019) (20)
Comparing Treatment Strategies for Stage I Small‐cell lung Cancer (2018) (19)
1383TiPBlood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC (2017) (19)
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). (2015) (18)
Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer (2019) (18)
Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. (2004) (18)
SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. (2009) (18)
Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study (2019) (18)
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study (2011) (18)
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial (2022) (18)
Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones (2015) (18)
Crizotinib: an anaplastic lymphoma kinase inhibitor. (2011) (17)
1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study (2017) (17)
Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC. (2020) (17)
Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer (2017) (17)
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. (2020) (17)
Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) andALKkinase domain mutations (2018) (17)
Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. (2020) (17)
Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety. (2018) (17)
The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions (2017) (17)
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer (2015) (16)
136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR) (2018) (16)
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. (2019) (16)
Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303). (2015) (16)
A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors. (2018) (16)
Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. (2012) (16)
Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). (2015) (16)
Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. (2006) (16)
Abstract 3364: Upregulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells (2011) (15)
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management (2016) (15)
Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC. (2018) (15)
Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). (2020) (15)
A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design (2003) (15)
Parameters for individualizing systemic therapy in non-small cell lung cancer. (2010) (14)
Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. (2021) (14)
Abstract B136: Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs (2015) (14)
3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement (2015) (14)
Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non–Small Cell Lung Cancer Patients (2019) (14)
Retreatment With Osimertinib Following Pneumonitis (2018) (14)
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer (2019) (14)
MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer (2017) (13)
Cost‐effectiveness and lung cancer clinical trials (2003) (13)
24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. (2018) (13)
Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer (2008) (12)
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma (2019) (12)
1222OA RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8). (2014) (12)
Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). (2010) (12)
Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors (2014) (12)
Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). (2016) (11)
Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility. (2022) (11)
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. (2021) (11)
Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC) (2019) (11)
Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer (NSCLC). (2004) (11)
SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC). (2012) (11)
Clinical presentation of non-small cell carcinoma of the lung (2012) (10)
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel (2021) (10)
A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. (2007) (10)
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC). (2019) (10)
Hope and realism: the perfect balance? (2011) (10)
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. (2020) (10)
Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). (2019) (10)
Lung Cancer Stem Cells: Current Progress and Future Perspectives (2013) (10)
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC (2020) (9)
Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189. (2016) (9)
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Preface. (2016) (9)
397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC) (2010) (9)
1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins) (2020) (9)
P3-136: A Phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations (2007) (9)
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study. (2020) (8)
SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. (2018) (8)
MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations (2021) (8)
Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients (pts) (2008) (8)
Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort. (2021) (8)
Histologic Transformation in NSCLC with PD‐1 therapy (2017) (8)
Is Histologic Subtype Significant in the Management of NSCLC (2010) (8)
Second‐Line Treatment Options in Non–Small‐Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology (2017) (8)
Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC (2018) (8)
The Optimal Chemotherapy for Stage III Non–Small Cell Lung Cancer Patients (2011) (8)
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial (2022) (8)
Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686. (2013) (8)
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. (2018) (8)
Retrospective review of cancer patients > or =80 years old treated with chemotherapy at a comprehensive cancer center. (2008) (7)
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. (2022) (7)
Abstract C30: Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI‐2358) combined with docetaxel in patients with non‐small cell lung cancer (NSCLC) (2009) (7)
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses. (2013) (7)
10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer (2014) (7)
O-110 Preliminary results of a phase II study of celecoxib and weekly docetaxel in elderly (> 70 yrs) or PS2 patients with advanced non-small cell lung cancer (NSCLC) (2003) (7)
COPD‐dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk (2019) (7)
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). (2016) (7)
The selective personalized radioimmunotherapy for locally advanced NSCLC trial (SPRINT). (2019) (7)
Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors (2021) (7)
AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study (2007) (7)
Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. (2017) (7)
OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update (2017) (7)
Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer. (2013) (7)
JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial (2017) (7)
OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC (2019) (6)
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. (2018) (6)
OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy (2021) (6)
Review: Adjuvant therapy for resected non-small cell lung cancer (2009) (6)
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer. (2019) (6)
MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR) (2017) (6)
Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). (2011) (6)
Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer. (2007) (6)
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation. (2022) (6)
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). (2018) (6)
Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic (2020) (6)
Rociletinib-associated cataracts in EGFR-mutant NSCLC (2016) (6)
Preoperative pulmonary rehabilitation for marginal-function lung cancer patients (2017) (6)
Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease. (2022) (6)
Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC). (2013) (5)
KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? (2018) (5)
3104 Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M (2015) (5)
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies (2019) (5)
Phase II Trial of Dose‐dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non–Small‐cell Lung Cancer (2017) (5)
MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma (2017) (5)
RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial. (2018) (5)
Using Radiolabeled 3′-Deoxy-3′-18F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non–Small Cell Lung Cancer (2018) (5)
New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent (2018) (5)
Neutrophil lymphocyte ratio (NLR) as a predictive biomarker for PD-1/PD-L1 directed therapy in metastatic non-small cell lung cancer (NSCLC). (2017) (5)
The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer (2019) (5)
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. (2021) (5)
Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528. (2009) (5)
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer (2018) (5)
Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. (2017) (5)
Novel combinations using pemetrexed in malignant mesothelioma. (2004) (4)
O10.3Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M (2015) (4)
NEURO/MEDICAL ONCOLOGY (2013) (4)
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors (2019) (4)
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES SCLC). (2010) (4)
P2.06-014 Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy: Topic: Phase II + NK (2017) (4)
P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung (2017) (4)
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC (2022) (4)
Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further? (2007) (4)
Whole-exome sequencing reveals genetic variability among lung cancer cases subphenotyped for emphysema. (2016) (4)
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. (2021) (4)
Abstract 4660: A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung cancer. (2013) (4)
Incidence of Neuregulin1 (NRG1) gene fusions across tumor types. (2018) (4)
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling. (2014) (4)
A phase IB trial of iniparib (BSI-201) in combination with carboplatin (C)/paclitaxel (P) in patients with non-small cell lung cancer (NSCLC). (2011) (4)
102PLUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung (2017) (4)
MA25.01 Pembrolizumab Plus Chemotherapy for Advanced NSCLC Without Tumor PD-L1 Expression: Pooled Analysis of KN021G, KN189 and KN407 (2019) (4)
Abstract LB-397: Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 bySTK11andKEAP1status (2020) (4)
Rapid real‐world data analysis of patients with cancer, with and without COVID‐19, across distinct health systems (2021) (3)
Abstract 2376: Improved progression-free survival (PFS) in patients with short tumor telomere length: Subgroup analysis from a randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced NSCLC . (2013) (3)
Cyclooxygenase 2 inhibition in patients with non–small cell lung cancer: Is this still a valid target for therapy? (2015) (3)
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results. (2022) (3)
New Targets in Non-Small Cell Lung Cancer (2013) (3)
MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC (2017) (3)
Subdividing NSCLC: reflections on the past, present, and future of lung cancer therapy. (2009) (3)
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC (2022) (3)
Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials. (2011) (3)
Dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in non-small cell lung cancer (NSCLC) cell lines. (2006) (3)
Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761). (2016) (3)
P3.02b-115 Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib (2017) (3)
O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC (2019) (3)
1310PSurvival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study (2017) (3)
Phase II study of fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy. (2003) (3)
Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC). (2010) (3)
A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC). (2016) (3)
LUX-LUNG 8: A RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB VS. ERLOTINIB IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG AS SECOND-LINE THERAPY FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY (2012) (3)
Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC). (2004) (3)
BMET-18ASSESSING CENTRAL NERVOUS SYSTEM (CNS) RESPONSE TO ALECTINIB IN TWO PHASE II STUDIES OF PRE-TREATED ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): RECIST VERSUS RANO CRITERIA (2015) (3)
P3.02c-011 A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors:Topic: Targeted Therapy (2017) (3)
Phase 1b of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). (2014) (3)
P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions (2019) (3)
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer. (2022) (3)
3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial (2015) (2)
Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC) (2020) (2)
Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies. (2016) (2)
Brain metastases (mets) in lung cancer patients (pts): Analysis of the Detroit Surveillance, Epidemiology and End Results (SEER) data. (2010) (2)
miRNA Targeted Therapy in Lung Cancer (2014) (2)
PS01.66: Biomarker Stratification of Outcomes of Third‐Generation EGFR TKI Therapy in Patients with Previously‐Treated Advanced NSCLC: Topic: Medical Oncology (2016) (2)
1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC (2020) (2)
MA09.02 Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G (2017) (2)
Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer (2022) (2)
Phase I clinical trial of XK469 in patients with chemo-refractory solid tumors. (2004) (2)
OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC (2021) (2)
A Phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations: P3-136 (2007) (2)
Abstract 442: Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189 (2021) (2)
The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin. (2011) (2)
A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations (2007) (2)
Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk (2019) (2)
Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients. (2013) (2)
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study (2023) (2)
89PDResults from OAK subgroup analyses: A randomized Phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC (2017) (2)
3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test (2015) (2)
New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer (2014) (2)
Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity (2021) (2)
A phase 2 clinical trial of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM) (2005) (2)
Current knowledge and therapies (2016) (2)
Plasma osteopontin and the prognosis of pleural mesothelioma. (2013) (2)
Frequency of anaplastic lymphoma kinase (ALK) positive tumors among African American non-small cell lung cancer (NSCLC) patients. (2012) (2)
Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non–Small‐Cell Lung Cancer (2017) (2)
Novel therapies and clinical management (2016) (2)
CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). (2021) (2)
Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer (2019) (2)
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders (2017) (2)
Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer. (2006) (2)
Abstract 927: Pretreatment and serial plasma assessments of EGFR mutations in NSCLC patients treated with rociletinib (CO-1686) (2015) (1)
Abstract S10-02: Using real-world data (RWD) from an integrated platform for rapid analysis of patients with cancer with and without COVID-19 across distinct health systems (2020) (1)
1616OMulticenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM) (2017) (1)
Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies (2016) (1)
Risk of lung cancer in Hodgkins (HL), non-Hodgkins (NHL) lymphoma and chronic lymphocytic leukemia (CLL) patients (pts): Analysis of the Surveillance Epidemiology and End Results (SEER) data (2008) (1)
Abstract 5227: Molecular profiling in African American NSCLC patients to identify novel potential driver mutations (2016) (1)
Pemetrexed (Pem) with pembrolizumab (Pembro) maintenance: A post hoc subgroup safety analysis of KEYNOTE-189. (2020) (1)
1220TiPMULTI-ARM, NONRANDOMIZED, OPEN-LABEL PHASE IB STUDY TO EVALUATE FP1039/GSK3052230 WITH CHEMOTHERAPY IN NSCLC AND MPM WITH DEREGULATED FGF PATHWAY SIGNALING. (2014) (1)
PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189 (2019) (1)
P3.02c-024 Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling: Topic: Targeted Therapy (2017) (1)
Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC) (2004) (1)
P1.01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study (2019) (1)
Lung Cancer: Overview (2009) (1)
P10.04 Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis (2021) (1)
Comparing treatment strategies for stage I small cell lung cancer: A National Cancer Database study. (2017) (1)
P2-220: Radiation pneumonitis (RP) in lung cancer patients treated with chemotherapy (CT) and thoracic radiation (TR): Retrospective analyses of patients treated at a comprehensive cancer center (2007) (1)
PS02.18 Characterization of Patients with KRAS-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Community Practice Setting: Topic: Medical Oncology (2017) (1)
Tribbles 2 confers enzalutamide resistance in prostate cancer by promoting lineage plasticity (2021) (1)
P3.02b-003 Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers: Topic: EGFR Biomarkers (2017) (1)
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC). (2022) (1)
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations (2022) (1)
Safety of lorlatinib in subgroups of patients from a phase I/II trial (2019) (1)
Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib results (2019) (1)
1307P Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD) (2020) (1)
108PDAFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8), A PHASE III GLOBAL TRIAL (2015) (1)
Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. (2022) (1)
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. (2011) (1)
Enhanced Therapeutic Efficacy By Radiation Therapy Combined With Axitinib in a Preclinical Model of Lung Carcinoma (2012) (1)
1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression (2020) (1)
1473PPHASE 1B TRIAL OF ANTI-NOTCH 2/3 ANTIBODY OMP-59R5 IN COMBINATION WITH ETOPOSIDE AND CISPLATIN (EP) IN PATIENTS (PTS) WITH UNTREATED EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ED-SCLC): THE PINNACLE STUDY. (2014) (1)
Association of the development of bone metastases with the development of brain metastases in patients with non-small cell lung cancer. (2013) (1)
A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC. (2022) (1)
Abstract A31: Assessment of EGFR mutations in matched urine, plasma and tumor tissue in NSCLC patients treated with rociletinib (CO-1686) (2015) (1)
Lung cancer in young patients (1998) (1)
A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer. (2018) (1)
Abstract CT104: A first-in-human phase I dose escalation study of BET inhibitor GSK2820151 in patients with advanced or recurrent solid tumors cancers (2017) (1)
Patient-Reported Outcomes in the Era of Immunotherapy Trials. (2021) (1)
P3.02b-103 Identification of On-Target Mechanisms of Resistance to EGFR Inhibitors Using ctDNA Next-Generation Sequencing: Topic: EGFR RES (2017) (1)
Approach to Anaplastic Lymphoma Kinase (ALK) Gene Rearranged Non–Small Cell Lung Cancer (NSCLC) (2019) (1)
A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET. (2020) (1)
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors (2022) (1)
Cardiac toxicity associated with dose and gender in patients undergoing chemoradiation for esophageal carcinoma. (2012) (1)
Targeted therapy in lung cancer: the good, the bad, and the ugly. (2009) (1)
OA23.03 Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial (2017) (1)
Abstract CT085: Safety of pemetrexed (Pem) plus platinum (Plat) in combination with pembrolizumab (Pembro) for metastatic nonsquamous NSCLC: A post hoc analysis of KEYNOTE-189 (2020) (1)
Phase II study of fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy (2004) (1)
P1.04-011 Development of Novel Blood-Based Biomarker Assays in 1L Advanced/Metastatic NSCLC: Blood First Assay Screening Trial (BFAST) (2017) (1)
1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses (2020) (1)
Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy. (2017) (1)
Differential Role of Soy Isoflavones in Radiotherapy of Lung Cancer: Augmenting Tumor Response and Protecting Normal Tissue (2011) (0)
Interplay of Cardiac and Pulmonary Toxicity: An Analysis of Prospective Trials for Locally Advanced Non-Small Cell Lung Cancer (2019) (0)
P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC) (2017) (0)
Brief Report: Prognostic relevance of 3q amplification in squamous cell carcinoma of the lung (2022) (0)
Daclatasvir, an antiviral drug, downregulates Tribbles 2 pseudokinase and re-sensitizes enzalutamide resistant prostate cancer cells. (2023) (0)
Targeting Oncogenic Driver Mutations in Lung Cancer (2023) (0)
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC (2022) (0)
A case of ovarian vein thrombosis in a patient with extensive stage small cell lung cancer with metastasis to the pancreas. (2017) (0)
Mutational load in tumors of African-American non-small cell lung cancer (NSCLC) patients. (2016) (0)
Abstract 398: Tribbles 2 confers resistance to anti-androgenic therapy in prostate cancer via lineage switching (2022) (0)
Clinical Radiation Pneumonitis After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer: Do Taxane-based Regimens Increase the Risk? (2015) (0)
Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation (2022) (0)
A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non–small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab. (2022) (0)
Utility of surveillance imaging in stage III non-small cell lung cancer (NSCLC) patients: A SEER-Medicare analysis. (2016) (0)
P10.03 Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors (2021) (0)
Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities (2022) (0)
Risk of second lung cancer in patients with previously treated lung cancer: Analysis of the Surveillance, Epidemiology and End Results (SEER) registry (2008) (0)
Phase I Study of Bryostatin1and Gemcitabine (2006) (0)
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST). (2022) (0)
P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors (2021) (0)
Blood-Based Early Detection of Malignant Mesothelioma. Authors' reply (2009) (0)
Phase IClinicalTrial of BMS-247550 , ADerivative of Epothilone B , Using AcceleratedTitration 2 BDesign (2005) (0)
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial (2015) (0)
456 A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress (2021) (0)
Impact of ErbB Mutations on Clinical Outcomes in Afatinib‐ or Erlotinib‐Treated Patients with SCC of the Lung: P13 (2018) (0)
A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non–small cell lung cancer (NSCLC) (RAMP 203). (2022) (0)
FGFR1 amplification in squamous cell lung cancers. (2012) (0)
LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy (2015) (0)
Multiplex testing of potentially ‘actionable’ alterations in small cell lung cancer (SCLC). (2014) (0)
COPD And Lung Cancer In African Americans (2010) (0)
Retraction to: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines (Cancer, 10.1002/cncr.24250) (2016) (0)
KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? (2018) (0)
Abstract CT032: A Phase 1b study of PEGPH20 plus pembrolizumab in patients with selected hyaluronan-high solid tumors (2017) (0)
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors (2022) (0)
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study. (2023) (0)
Abstract 5587: Serial monitoring ofEGFRmutations in plasma and evaluation ofEGFRmutation status in matched tissue and plasma from NSCLC patients treated with CO-1686 (2014) (0)
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management (2022) (0)
Abstract 1435: Immune/inflammatory polymorphisms predict lung cancer survival (2017) (0)
Fast Neutron Radiotherapy for Advanced Stage Non-small Cell Lung Cancer (2010) (0)
Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189 (2022) (0)
Molecular Imaging Program Annual Retreat “ Molecular Imaging for Selection and Monitoring of Individualized Cancer Therapies ” (2016) (0)
Salvage Fast Neutron Radiotherapy for Treatment of Refractory Non-small Cell Lung Cancer (2010) (0)
Blood-based early detection of malignant mesothelioma (2009) (0)
Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer III trial: Analysis of long-term response to second- line afatinib in patients with advanced squamous cell carcinoma (SCC) (2017) (0)
Does preoperative pulmonary rehabilitation effect outcomes in patients with low forced expiratory volume in 1 second undergoing lung cancer resection (2013) (0)
Characteristics and outcomes of cancer patients ≥80 years treated with chemotherapy at a comprehensive cancer center. (2006) (0)
Abstract IA15: Lung cancer genomics (2017) (0)
Role of Notch-1 in epithelial-to-mesenchymal transition-induced erlotinib resistance of non-small cell lung cancer (NSCLC) cells. (2014) (0)
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status (2021) (0)
A 67-Year-Old Woman With Right Lung Mass: A Rare Diagnosis (2010) (0)
P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome (2021) (0)
Effect of GDC-0449, a hedgehog (Hh) pathway inhibitor, on tumor activity and on erlotinib and cisplatin in a xenograft model of non-small cell lung cancer (NSCLC) with activated Hh pathway. (2012) (0)
Maintenance Chemotherapy for Advanced Non-small-cell Lung Cancer (2010) (0)
1343PEfficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs (2017) (0)
IM01.01 4-Year Survival in Randomised Phase II (POPLAR) and Phase III (OAK) Studies of Atezolizumab vs. Docetaxel in 2L+ NSCLC (2021) (0)
Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC) (2017) (0)
Health‐Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non‐Squamous NSCLC: KEYNOTE‐189: PD.1.01 (2018) (0)
732 First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21–1480, an affinity-balanced PD-L1x4–1BBxHSA trispecific antibody: results of phase 1 dose escalation (2022) (0)
Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis. (2023) (0)
Dr. Gadgeel on Docetaxel Plus Trametinib in KRAS-Mutated Recurrent NSCLC (2019) (0)
Radiographic parameters in predicting outcome of patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab. (2013) (0)
1414 Racial ethnic differences in treatment of advanced non-small cell lung cancer with immune checkpoint inhibitors: analysis of a large real-world dataset (2022) (0)
Clinical Outcome in Patients With Early-Stage Small Cell Lung Cancer Treated With Surgery or Radiation in the Absence of Prophylactic Cranial Irradiation: A Single-Center Retrospective Study (2023) (0)
A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM). (2006) (0)
Retraction to: Response to dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor (Cancer, 10.1002/cncr.23100) (2016) (0)
Outcomes of patients with malignant pleural mesothelioma (MPM) following the approval cisplatin/pemetrexed: Experience of a comprehensive cancer center. (2012) (0)
446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers (2016) (0)
PS02.22 Alectinib Following Prior ALK Tyrosine Kinase Inhibitor (TKI) Therapy: Results from the US Expanded Access Program (EAP): Topic: Medical Oncology (2017) (0)
Multiplex testing of driver mutations in non-small cell lung cancer (NSCLCs) of African-American (AA) patients. (2013) (0)
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. (2015) (0)
Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer. (2016) (0)
Radiation Dose to the Heart and Mortality in Patients Receiving Definitive Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer (2016) (0)
Issue information (2015) (0)
Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation (2023) (0)
Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting-Aug 5, 2022 (2022) (0)
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma (2023) (0)
Abstract 258: Characterizing cancer gene mutations in non-small cell lung cancer from African American patients (2014) (0)
The impact of bevacizumab on the occurrence and recurrence of intracranial brain metastases in non-small cell lung cancer (NSCLC) patients. (2012) (0)
H02*Afatinib vs erlotinib as second-line therapy of patients with advanced SCC of the lung following platinum-based chemotherapy: OS analysis from the global phase III trial LUX-Lung 8 (LL8) (2015) (0)
Race-specific genomic determinants of therapeutic response in African American NSCLC patients. (2022) (0)
Abstract CT229: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors (2023) (0)
Radiation pneumonitis (RP) in lung cancer patients treated with chemotherapy (CT) and thoracic radiation (TR): Retrospective analyses of patients treated at a comprehensive cancer center (2007) (0)
Acknowledgment of Reviewers 2021. (2021) (0)
734 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors (2022) (0)
Abstract 2228: Oncogenomic profiling of NSCLC: A pilot study (2010) (0)
A phase II randomized, placebo-controlled trial evaluating nintedanib versus placebo as prophylaxis against radiation pneumonitis in patients with unresectable non-small cell lung cancer (NSCLC ) undergoing chemoradiation therapy (CRT): A National Comprehensive Cancer Network-sponsored study. (2016) (0)
Clinical Presentation and Diagnosis of Non-Small Cell Lung Neoplasms (2018) (0)
Abstract LB-264: Axitinib improves radiotherapy for murine xenograft lung tumors (2012) (0)
A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC). (2022) (0)
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy. (2023) (0)
MA21.01 Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC (2018) (0)
Prevalence of COPD in a lung cancer case-control study: Variability by assessment method and by race. (2014) (0)
Cancer is chronic but antimicrobial stewardship is iconic: A retrospective cohort of optimal antibiotic use in ambulatory oncology clinics (2023) (0)
Abstract B54: Relationship between aspirin use and lung cancer risk differs based on race (2017) (0)
ALK Resistance Mutations in ALK-Positive Lung Cancer (2016) (0)
Maintenance Pembrolizumab Did Not Improve PFS in Small-Cell Lung Cancer (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Shirish M. Gadgeel?

Shirish M. Gadgeel is affiliated with the following schools:

MD Anderson Cancer Center
University of Michigan
Wayne State University
Stanford University
University of Las Palmas de Gran Canaria
New York University